Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.

Tumori - 1 Jan 2000

Zheng Yulong, Fang Weijia, Liu Xiao, Xu Nong

Abstract excerpt

Icotinib is a new oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). We report on a 49-year-old man with recurrent lung adenocarcinoma treated with icotinib. The patient obtained a partial remission in 4 weeks that was maintained 14 months. Retrospective examination of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Crown Ethers
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Neoplasm Recurrence, Local

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 23052173
DOI: 10.1177/030089161209800422

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23052173-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.PMID 23052173Read ↗

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.Semantic proximity Read ↗

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.Semantic proximity Read ↗

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.Semantic proximity Read ↗

Icotinib: efficacy in different solid tumors and gene mutations.Semantic proximity Read ↗

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Semantic proximity Read ↗

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.